Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Nov-Dec;15(7):696-704.
doi: 10.4158/EP09117.ORR.
Affiliations
- PMID: 19625243
- DOI: 10.4158/EP09117.ORR
Randomized Controlled Trial
Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia
Ambika Babu et al. Endocr Pract. 2009 Nov-Dec.
Abstract
Objective: To investigate the safety and effectiveness of 2 simple discharge regimens for use in patients with type 2 diabetes mellitus (DM2) and severe hyperglycemia, who present to the emergency department (ED) and do not need to be admitted.
Methods: We conducted an 8-week, open-label, randomized controlled trial in 77 adult patients with DM2 and blood glucose levels of 300 to 700 mg/dL seen in a public hospital ED. Patients were randomly assigned to receive glipizide XL, 10 mg orally daily (G group), versus glipizide XL, 10 mg orally daily, plus insulin glargine, 10 U daily (G+G group). The primary outcome was to maintain safe fasting glucose and random glucose levels of <350 and <500 mg/dL up to 4 weeks and <300 and <400 mg/dL, respectively, thereafter and to have no return ED visits (responders).
Results: Baseline characteristics were similar between the 2 treatment groups. The primary outcome was achieved in 87% of patients in both treatment groups. The enrollment mean blood glucose values of 440 and 467 mg/dL in the G and G+G groups, respectively, declined by the end of week 1 to 298 and 289 mg/dL and by week 8 to 140 and 135 mg/dL, respectively. Homeostasis model assessment of beta-cell function and early insulin response improved 7-fold and 4-fold, respectively, in responders at the end of the 8-week study.
Conclusion: Sulfonylurea with and without use of a small dose of insulin glargine rapidly improved blood glucose levels and beta-cell function in patients with DM2. Use of sulfonylurea alone once daily can be considered a safe discharge regimen for such patients and an effective bridge between ED intervention and subsequent follow-up.
Similar articles
- Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia.
Amblee A, Lious D, Fogelfeld L. Amblee A, et al. J Clin Endocrinol Metab. 2016 Jun;101(6):2528-35. doi: 10.1210/jc.2015-4097. Epub 2016 May 4. J Clin Endocrinol Metab. 2016. PMID: 27144930 Clinical Trial. - Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
Feinglos MN, Thacker CR, Lobaugh B, DeAtkine DD, McNeill DB, English JS, Bursey DL. Feinglos MN, et al. Diabetes Res Clin Pract. 1998 Mar;39(3):193-9. doi: 10.1016/s0168-8227(98)00003-5. Diabetes Res Clin Pract. 1998. PMID: 9649951 Clinical Trial. - Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Yoshihara T, Kumashiro N, Kanazawa Y, Mita T, Sakurai Y, Kawai J, Abe M, Motojima K, Hara K, Yamazaki Y, Kanazawa A, Miwa S, Sato F, Kanno R, Shimizu T, Sakai K, Uchino H, Watada H, Tanaka Y, Kawamori R, Hirose T. Yoshihara T, et al. Endocr J. 2006 Feb;53(1):67-72. doi: 10.1507/endocrj.53.67. Endocr J. 2006. PMID: 16543674 Clinical Trial. - Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F, Carabino JM, Vergara CM. Wang F, et al. Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. doi: 10.1016/s0149-2918(03)80156-x. Clin Ther. 2003. PMID: 12860485 Review. - Next-gen therapeutics to spare and expand beta-cell mass.
Bolla AM, Usuelli V, Ben Nasr M, Frigerio S, Loretelli C, D'Addio F, Fiorina P. Bolla AM, et al. Curr Opin Pharmacol. 2021 Dec;61:77-82. doi: 10.1016/j.coph.2021.09.001. Epub 2021 Oct 11. Curr Opin Pharmacol. 2021. PMID: 34649215 Review.
Cited by
- From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.
Dave BP, Chorawala MR, Shah IV, Shah NN, Bhagat SU, Prajapati BG, Thakkar PC. Dave BP, et al. Mol Biol Rep. 2024 Jul 23;51(1):835. doi: 10.1007/s11033-024-09793-y. Mol Biol Rep. 2024. PMID: 39042283 Review. - 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.
American Diabetes Association Professional Practice Committee. American Diabetes Association Professional Practice Committee. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. Diabetes Care. 2024. PMID: 38078590 Review. - 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. ElSayed NA, et al. Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009. Diabetes Care. 2023. PMID: 36507650 Free PMC article. Review. - From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Mosenzon O, Del Prato S, Schechter M, Leiter LA, Ceriello A, DeFronzo RA, Raz I. Mosenzon O, et al. Cardiovasc Diabetol. 2021 Apr 28;20(1):92. doi: 10.1186/s12933-021-01281-y. Cardiovasc Diabetol. 2021. PMID: 33910583 Free PMC article. Review. - Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia.
He M, Deng M, Wang J, Fan P, Wang Y, Zhao X, He Y, Shi B, Sui J. He M, et al. Exp Ther Med. 2021 Mar;21(3):217. doi: 10.3892/etm.2021.9649. Epub 2021 Jan 15. Exp Ther Med. 2021. PMID: 33574913 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical